Skip to main content

Table 3 Expression of pgp, bcrp, mrp1 and mrp3 in various experimental conditions

From: Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells

Efflux pump Sample Relative expression in cell lines
CMT-U27 CMT-U309 P114 CMT-W1 CMT-W2
PGP ctrl 3.50 9.20 5.00 17.85 16.42
pgp siRNA 0.45*** 0.10*** 0.50*** 0.80*** 0.16***
non-coding siRNA 3.44 9.10 5.10 7.750 16.31
vinblastine 9.50*** 16.20*** 14.70*** 19.56*** 21.52***
cisplatin 8.95*** 35.20*** 31.00*** 36.08*** 26.16***
  cyclophosphamide 0.09*** 2.30** 0.22*** 0.08*** 2.87***
BCRP ctrl 19.84 11.86 23.52 23.70 36.00
bcrp siRNA 17.15** 2.77*** 2.77*** 10.46*** 0.00***
non-coding siRNA 19.00 11.20 22.90 23.00 36.18
vinblastine 14.84* 3.80*** 11.80*** 12.30*** 13.24*
cisplatin 30.50*** 22.16*** 40.34*** 36.57*** 37.23*
  cyclophosphamide 23.32*** 33.53* 29.23*** 24.50* 41.72**
MRP1 ctrl 7.50 9.40 16.50 20.10 24.02
mrp1 siRNA 0.10*** 0.60*** 0.23*** 0.20*** 0.61***
non-coding siRNA 7.20 6.62 20.12 20.91 24.21
vinblastine 9.70*** 7.00*** 9.76*** 35.01* 30.20***
cisplatin 15.70*** 19.34** 21.84* 30.61*** 26.20**
  cyclophosphamide 2.50** 0.09*** 3.32*** ↓0.40*** 6.04**
MRP3 ctrl 14.40 23.28 13.84 17.70 11.35
mrp3 siRNA 1.00*** 0.00*** 4.84*** 13.90** 7.15**
non-coding siRNA 13.87 21.99 13.09 17.10 10.99
vinblastine 14.20 21.97 13.12 17.50 9.78
cisplatin 15.60* 32.20*** 15.80* 21.30*** 14.09*
  cyclophosphamide 14.99 24.09 14.25 18.01 11.72
  1. Expression of efflux pumps in canine mammary cell lines in control conditions, after scrambled siRNA treatment and pgp, bcrp, mrp1 and mrp3 -specific siRNA treatment as well as after treatment with vinblastine, cisplatin and cyclophosphamide at IC50 doses. p < 0.05 was marked as*, p < 0.01 was marked as **, and p < 0.001 was marked as ***. One-way ANOVA followed by Tukey HSD post-hoc test were applied. Increase in expression was marked as red text, decreased in expression was marked as green text, whereas no change in transcript level was marked as black text.